Chat With UsChat With UsBy Mir Moomin • 3 March 2026
Lynk Pharmaceuticals has reported positive topline results from its Phase 3 trial of zemprocitinib, a next-generation JAK1 inhibitor, in patients with moderate-to-severe atopic dermatitis. The study met all primary and key secondary endpoints, demonstrating significant efficacy along with a favorable safety profile that could help differentiate it from earlier JAK inhibitors.
The multicenter, randomized, double-blind, placebo-controlled trial enrolled 356 patients who received either 12 mg or 24 mg of zemprocitinib or placebo. At week 16, both dose groups showed statistically significant improvements compared to placebo across the study’s primary endpoints.
One of the main measures was EASI-75, which reflects a 75 percent improvement in eczema severity. The data showed that 38.1 percent more patients in the 12 mg group and 46.4 percent more patients in the 24 mg group achieved EASI-75 compared to placebo. The Investigator’s Global Assessment for atopic dermatitis, or vIGA-AD, also demonstrated clear superiority in both treatment groups.
Beyond overall skin clearance, patients experienced meaningful relief from symptoms such as itching. On the itch severity scale, more than 31 percent of patients in both dose groups achieved better outcomes than those receiving placebo. Additional secondary endpoints, including EASI-50, EASI-90, SCORAD, Dermatology Life Quality Index, and Patient-Oriented Eczema Measure scores, were all significantly improved. Some benefits were observed as early as two weeks, suggesting a relatively rapid onset of action.
Safety findings were consistent with prior studies. Most adverse events were mild to moderate, and no new safety signals were identified. Rates of serious adverse events and laboratory changes, including hemoglobin levels, white blood cell counts, and liver enzymes, were comparable to placebo. This is particularly relevant given the broader safety scrutiny surrounding the JAK inhibitor class.
Company leadership described the results as a strong validation of its strategy in immune and inflammatory diseases. The Phase 3 success in eczema follows recent positive data in rheumatoid arthritis for the same compound. Lynk plans to pursue regulatory submissions for the eczema indication and continue evaluating zemprocitinib across additional autoimmune conditions.
If confirmed in further analyses, zemprocitinib could emerge as a new oral treatment option for moderate-to-severe atopic dermatitis and a competitive next-generation JAK1 therapy in the evolving immunology landscape.